Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Talis Biomedical Corp (TLIS)
|
Add to portfolio |
|
|
|
| Price: |
$4.02
| | Metrics |
| OS: |
3.81
|
M
| |
-89
|
% ROE
|
| Market cap: |
$15.3
|
M
| |
-440
|
% ROIC
|
|
Net cash:
|
$98.2
|
M
| |
$25.77
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($82.5)
|
M
| |
|
|
|
EBIT
|
($90.3)
|
M
| |
|
|
| EPS |
($10.93)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 4.8 | 8.2 | 10.9 | 23.8 | 18.4 |
| Revenue growth | -41.3% | -25.1% | -54.1% | 29.5% | |
| Cost of goods sold | 8.4 | 0.0 | 0.0 | 30.7 | 23.8 |
| Gross profit | -3.6 | 8.2 | 10.9 | -6.9 | -5.4 |
| Gross margin | -74.4% | 100.0% | 100.0% | -28.8% | -29.5% |
| Selling, general and administrative | 40.7 | 42.4 | 13.1 | | |
| Research and development | 70.8 | 157.6 | 89.0 | | |
| General and administrative | | | | 6.9 | 5.4 |
| EBIT | -115.1 | -191.8 | -91.2 | -26.7 | -21.4 |
| EBIT margin | -2392.7% | -2341.2% | -833.6% | -112.1% | -116.5% |
| Pre-tax income | -113.0 | -192.0 | -91.1 | 26.4 | -21.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -113.0 | -192.0 | -91.1 | 26.4 | -21.3 |
| Net margin | -2348.5% | -2343.9% | -833.2% | 110.8% | -116.0% |
| |
| Diluted EPS | ($4.24) | ($8.48) | ($42.98) | $12.27 | ($40.62) |
| Shares outstanding (diluted) | 26.6 | 22.7 | 2.1 | 2.2 | 0.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|